Skip to content
Catalyst

propranololWhat was measured

Measured, with no finding

601 endpoints

Show what was measuredHide what was measured
  • Gastrointestinal hemorrhage, pooled risk difference

    decreases

    Pooled risk differences of gastrointestinal hemorrhage were -18 % [95 % CI, -25 %, -10 %] in all trials

    PMID 12918133 · one of two readings recorded this

  • Gastrointestinal hemorrhage, pooled risk difference

    decreases

    -11 % [95 % CI, -21 %, -1 %] in primary prevention trials

    PMID 12918133 · one of two readings recorded this

  • Gastrointestinal hemorrhage, pooled risk difference

    decreases

    -25 % [95 % CI, -39 %, -10 %] in secondary prevention trials

    PMID 12918133 · one of two readings recorded this

  • Total deaths, number of patients

    decreases

    A total of 440 patients died, 188 in propranolol groups and 252 in control groups

    PMID 12918133 · one of two readings recorded this

  • Total mortality, pooled risk difference

    decreases

    Pooled risk differences of total death were -7 % [95 % CI, -12 %, -3 %] in all trials

    PMID 12918133 · one of two readings recorded this

  • Total mortality, pooled risk difference

    decreases

    -9 % [95 % CI, -18 %, -1 %] in primary prevention trials

    PMID 12918133 · one of two readings recorded this

  • Total mortality, pooled risk difference

    decreases

    -5 % [95 % CI, -9 %, -1 %] in secondary prevention trials

    PMID 12918133 · one of two readings recorded this

  • clinical effectiveness of propranolol versus systemic steroids in airway haemangiomas (35 children), and percentage airway obstruction before and after propranolol (21 patients)

    increases, n = 35

    Not recorded as a finding: the comparison was against another active treatment

    Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%).

    PMID 23093810 · one of two readings recorded this

  • comparative outcome of propranolol versus systemic steroids in airway haemangiomas (35 children, chi-square); airway obstruction percentage before and after propranolol (paired t-test)

    increases, propranolol outperformed steroids in 33 cases (94%), steroids superior in two (6%), n = 35

    Not recorded as a finding: the comparison was against another active treatment

    Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%).

    PMID 23093810 · one of two readings recorded this

  • Comparative outcome, propranolol better than systemic steroids

    increases, p = 0.001

    Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%). The result was statistically significant (p < 0.001)

    PMID 23093810 · one of two readings recorded this

  • Failure to respond to propranolol

    Four children from our study population failed to respond to propranolol treatment (6.5%), and in seven the haemangioma relapsed after discontinuation of treatment (11.5%)

    PMID 23093810 · one of two readings recorded this

  • Mean airway obstruction

    decreases, p = 0.001

    The mean obstruction before the administration of propranolol was 72%, and after intervention was 20%. The result proved statistically significant (p < 0.001)

    PMID 23093810 · one of two readings recorded this

  • Mean follow-up duration

    Treated children were followed up for a mean of 8.4 months

    PMID 23093810 · one of two readings recorded this

  • Mean referral age

    The mean referral age for children with airway haemangiomas was 2.4 months (range 0.7-8 months)

    PMID 23093810 · one of two readings recorded this

  • Mean starting age of propranolol treatment

    the mean starting age of propranolol treatment 5.1 months (range 0.75-22 months)

    PMID 23093810 · one of two readings recorded this

  • Relapse after discontinuation of propranolol

    Four children from our study population failed to respond to propranolol treatment (6.5%), and in seven the haemangioma relapsed after discontinuation of treatment (11.5%)

    PMID 23093810 · one of two readings recorded this

  • Subsequent recall of negatively valenced emotional material after pre-consolidation dosing

    decreases, n = 259

    propranolol given before memory consolidation reduced subsequent recall for negatively valenced stories, pictures and word lists (Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74)

    PMID 23182304 · one of two readings recorded this

  • Subsequent recall of negatively valenced emotional words and cue-elicited fear responses after pre-reconsolidation dosing

    decreases, n = 308

    Propranolol before reconsolidation also reduced subsequent recall for negatively valenced emotional words and the expression of cue-elicited fear responses (Hedges g = 0.56, 95% CI 0.13-1.00)

    PMID 23182304 · one of two readings recorded this

  • subsequent recall of negatively valenced stories, pictures and word lists after propranolol before consolidation; cue-elicited fear responses after reconsolidation; Hedges g

    decreases, Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74

    Not recorded as a finding: this platform holds no node for the endpoint

    Compared with placebo, propranolol given before memory consolidation reduced subsequent recall for negatively valenced stories, pictures and word lists (Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74).

    PMID 23182304 · one of two readings recorded this

  • Efficacy in infantile haemangiomas, pooled

    increases, p = 0.001

    The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.02

    laser treatment (OR = 9.00, 95% CI 1.42, 57.12, P = 0.020)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.001

    propranolol was a more effective therapy when compared with steroids (OR = 9.67, 95% CI 6.61, 14.15, P < 0.001)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.003

    vincristine (OR = 9.00, 95% CI 2.15, 37.66, P = 0.003)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.001

    cutaneous IHs (OR = 24.95, 95% CI 9.48, 65.64, P < 0.001)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.001

    infantile airway haemangiomas (OR = 20.91, 95% CI 7.81, 55.96, P < 0.001)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.033

    infantile hepatic haemangiomas (OR = 9.89, 95% CI 1.20, 81.54, P = 0.033)

    PMID 24033819 · one of two readings recorded this

  • Efficacy in infantile haemangiomas

    increases, p = 0.001

    peri-ocular IHs (OR = 9.39, 95% CI 3.88, 22.71, P < 0.001)

    PMID 24033819 · one of two readings recorded this

  • efficacy of propranolol in infantile haemangiomas, pooled odds ratio against other therapies (steroids, vincristine, laser)

    increases, OR = 9.67, 95% CI 6.62, 14.12

    Not recorded as a finding: the comparison was against another active treatment

    The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001).

    PMID 24033819 · one of two readings recorded this

  • efficacy of propranolol in infantile haemangiomas versus other therapies (steroids, vincristine, laser), pooled odds ratio

    increases, OR = 9.67, 95% CI 6.62, 14.12

    Not recorded as a finding: the comparison was against another active treatment

    The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001).

    PMID 24033819 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas, pooled

    The pooled OR for effectiveness was 0.55 (95%CI, 0.43–0.67

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas, pooled

    the OR was 0.56 (95%CI, 0.50–0.61

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas, pooled

    The pooled odd ratio (OR) for effectiveness was 0.92 (95% CI, 0.89–0.95)

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas, pooled

    0.55 (95%CI, 0.28–0.81

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas, pooled

    In the pooled analysis, the OR was 0.68 (95%CI, 0.59–0.76

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    < 2 | 4 | 0.90 (0.79, 1.00) | 89 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    Asian | 9 | 0.96 (0.93, 0.99) | 85.4 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    Europe | 14 | 0.91 (0.86, 0.96) | 89.3 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    United States | 7 | 0.86 (0.77, 0.95) | 86.1 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    Head and Neck | 8 | 0.89 (0.81, 0.97) | 88.1 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    Head, Neck and others | 17 | 0.88 (0.84, 0.93) | 90.4 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    No | 15 | 0.95 (0.91, 0.98) | 88 | <0.001

    PMID 26375455 · one of two readings recorded this

  • Effectiveness (response) in infantile hemangiomas

    Yes | 15 | 0.88 (0.83, 0.93) | 86.5 | <0.001

    PMID 26375455 · one of two readings recorded this

  • HAM-A after 2-6 weeks of treatment (meta-analysis III), sensitivity analysis excluding study at high risk of selective reporting

    no effect, p = 0.16

    two trials, 63 participants in total; MD = 5.76 [–2.27 to 13.79], Z = 1.41, p = 0.16

    PMID 26487439 · one of two readings recorded this

  • HAM-A after 2-6 weeks of treatment (meta-analysis III)

    no effect, p = 0.32

    No significant overall effect was found (mean difference = −2.20, 95%-CI [–8.49; 4.09], Z = 0.99, p = 0.32)

    PMID 26487439 · one of two readings recorded this

  • HAM-A after 2 weeks of treatment (meta-analysis II)

    no effect, p = 0.78

    No significant difference was found between propranolol and benzodiazepines (mean difference = 2.81, 95%-CI [–16.87; 22.49], Z = 0.28, p = 0.78)

    PMID 26487439 · one of two readings recorded this

  • HAM-A after 6 weeks of treatment (meta-analysis IV)

    no effect, p = 0.8

    No significant difference was found between propranolol and alprazolam (mean difference = 0.51, 95%-CI [–3.39; 4.42], Z = 0.26, p = 0.80)

    PMID 26487439 · one of two readings recorded this

  • Hamilton Anxiety Rating Scale (HAM-A) after 2 weeks of treatment, propranolol versus benzodiazepines in panic disorder, pooled weighted mean difference

    no effect, mean difference = 2.81, 95%-CI [–16.87; 22.49], p = 0.78, n = 50

    Not recorded as a finding: the comparison was against another active treatment

    No significant difference was found between propranolol and benzodiazepines (mean difference = 2.81, 95%-CI [–16.87; 22.49], Z = 0.28, p = 0.78).

    PMID 26487439 · one of two readings recorded this

  • number of panic attacks after 2 weeks, and HAM-A anxiety scores at 2 to 6 weeks, pooled weighted mean difference of oral propranolol versus benzodiazepines (alprazolam, diazepam) in panic disorder with or without agoraphobia

    no effect, p = 0.43

    Not recorded as a finding: the comparison was against another active treatment

    No significant difference was found between propranolol and benzodiazepines (mean difference = 1.58, 95%-CI [–2.33; 5.50], Z = 0.79, p = 0.43).

    PMID 26487439 · one of two readings recorded this

  • number of panic attacks after 2 weeks of treatment (meta-analysis I)

    no effect, p = 0.43

    No significant difference was found between propranolol and benzodiazepines (mean difference = 1.58, 95%-CI [–2.33; 5.50], Z = 0.79, p = 0.43)

    PMID 26487439 · one of two readings recorded this

  • physiologic responding during mental imagery of traumatic event, 1 week later

    decreases, p = 0.007

    statistically reduced physiological responding (reduced heart rate and skin conductance) during imaginary exposure 1 week later (F(3,15) = 5.1; p = 0.007, η2 = 0.49)

    PMID 26487439 · one of two readings recorded this

  • self-reported anxiety at injection

    decreases, p = 0.033

    self-reported anxiety at injection: 5.5 (2.75) versus 7.45 (2.0), p = 0.033, one-tailed

    PMID 26487439 · one of two readings recorded this

  • self-reported trait anxiety

    no effect

    One 3-week crossover trial with specific (animal type: snake or spider) phobia subjects by reported no significant effects of propranolol on self-reported trait anxiety

    PMID 26487439 · one of two readings recorded this

  • state and trait anxiety at 6 months follow-up after social skills training

    no effect

    It reported absence of statistically significant effects of propranolol on state and trait anxiety 6 months follow-up after a social skills training

    PMID 26487439 · one of two readings recorded this

  • all-cause mortality

    increases, p = 0.01

    <1 year of prescriptionsc | 1012 | 4512 | 17,074 | 1.23 (0.98, 1.55) | 0.08 | 89% (<0.01) | 1.22 (1.04, 1.43) | 0.02 | 75% (<0.01) | 1.19 (1.04, 1.36) | 0.01 | 54% (0.03)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.16

    <1 year of prescriptionsc | 548 | 3099 | 10,977 | 1.01 (0.78, 1.32) | 0.92 | 85% (<0.01) | 1.20 (0.93, 1.53) | 0.16 | 83% (<0.01) | 1.15 (0.95, 1.39) | 0.16 | 62% (0.01)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    increases, p = 0.001

    Any beta-blocker | 25,472 | 133,251 | 570,968 | 1.57 (1.41, 1.75) | <0.001 | 92% (<0.001) | 1.12 (1.05, 1.20) | <0.001 | 65% (0.006)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    increases, p = 0.02

    Non-selective bb userb | 1732 | 7931 | 27,624 | 1.34 (1.14, 1.58) | 0.001 | 87% (<0.01) | 1.22 (1.09, 1.36) | 0.001 | 70% (<0.01) | 1.16 (1.02, 1.32) | 0.02 | 71% (<0.01)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    increases, p = 0.001

    Non-selective beta-blocker | 31,556 | 139,760 | 664,448 | 1.30 (1.14, 1.49) | <0.001 | 80% (<0.001) | 1.13 (1.06, 1.21) | <0.001 | 27% (0.21)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.06

    Non-selective beta-blocker | 25,487 | 133,251 | 571,213 | 1.35 (1.17, 1.55) | <0.001 | 78% (<0.001) | 1.14 (0.99, 1.30) | 0.06 | 68% (0.003)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect

    once this was removed the pooled estimate was attenuated slightly (fully adjusted HR = 1.03, 95% CI, 0.88, 1.20)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.27

    Propranolol userb | 818 | 4746 | 16,202 | 1.04 (0.86, 1.27) | 0.68 | 82% (<0.01) | 1.13 (0.93, 1.37) | 0.21 | 81% (<0.01) | 1.09 (0.93, 1.28) | 0.27 | 65% (0.006)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.68

    Propranolol userb | 818 | 4746 | 16,202 | 1.04 (0.86, 1.27) | 0.68 | 82% (<0.01) | 1.13 (0.93, 1.37) | 0.21 | 81% (<0.01) | 1.09 (0.93, 1.28) | 0.27 | 65% (0.006)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.68

    Propranolol | 31,556 | 139,760 | 664,448 | 0.97 (0.86, 1.09) | 0.60 | 44% (0.09) | 1.02 (0.94, 1.10) | 0.68 | 0% (0.54)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    no effect, p = 0.62

    Propranolol | 25,487 | 133,251 | 571,213 | 1.02 (0.89, 1.16) | 0.82 | 48% (0.06) | 1.04 (0.89, 1.21) | 0.62 | 48% (0.06)

    PMID 27906047 · one of two readings recorded this

  • all-cause mortality

    increases, p = 0.02

    Propranolol in stages 1–3c | 17,219 | 96,097 | 382,1512 | 1.07 (0.93, 1.24) | 0.32 | 29% (0.21) | 1.13 (1.02, 1.24) | 0.02 | 0% (0.46)

    PMID 27906047 · one of two readings recorded this

  • aromatase inhibitor use in the year after diagnosis

    increases

    There was a higher use of hormone antagonists (tamoxifen 39% versus 30% and aromatase inhibitors 26% versus 23%, respectively) in propranolol users versus non-users

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality, fully adjusted pooled HR

    no effect, HR = 0.94, 95% CI, 0.77, 1.16

    Not recorded as a finding: No outcome node for cancer-specific mortality (only all-cause and cardiovascular mortality exist).

    Overall, there was little difference in breast cancer-specific mortality or all-cause mortality in propranolol users compared with non-users after diagnosis (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively).

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality, pooled fully adjusted hazard ratio, propranolol use after diagnosis

    no effect, HR = 0.94, 95% CI 0.77-1.16

    Not recorded as a finding: No outcome node for cancer-specific mortality (cardiovascular-mortality node is cause-specific to CVD only)

    Overall, there was little difference in breast cancer-specific mortality or all-cause mortality in propranolol users compared with non-users after diagnosis (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively).

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.36

    <1 year of prescriptionsc | 145 | 1466 | 4555 | 1.13 (0.93, 1.37) | 0.22 | 22% (0.27) | 1.16 (0.99, 1.37) | 0.07 | 0% (0.55) | 1.10 (0.90, 1.34) | 0.36 | 0% (0.70)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.96

    <1 year of prescriptionsc | 88 | 1217 | 3703 | 1.00 (0.79, 1.26) | 0.98 | 22% (0.27) | 1.09 (0.88, 1.35) | 0.42 | 9% (0.35) | 1.01 (0.80, 1.27) | 0.96 | 0% (0.62)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.1

    Any beta-blocker | 5419 | 55,252 | 181,714 | 1.25 (1.11, 1.40) | <0.001 | 63% (0.03) | 1.07 (0.99, 1.16) | 0.10 | 0% (0.82)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.9

    Non-selective bb userb | 204 | 2349 | 6706 | 1.08 (0.94, 1.24) | 0.31 | 0% (0.51) | 1.07 (0.93, 1.23) | 0.37 | 0% (0.92) | 1.01 (0.85, 1.20) | 0.90 | 0% (0.47)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.45

    Non-selective beta-blocker | 6883 | 53,870 | 215,978 | 1.09 (0.95, 1.25) | 0.22 | 0% (0.47) | 1.05 (0.92, 1.21) | 0.45 | 0% (0.68)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.35

    Non-selective beta-blocker | 5426 | 55,252 | 181,959 | 1.10 (0.87, 1.39) | 0.43 | 51% (0.09) | 1.15 (0.85, 1.56) | 0.35 | 60% (0.04)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.56

    Propranolol userb | 128 | 1770 | 4989 | 0.92 (0.77, 1.10) | 0.36 | 0% (0.75) | 0.97 (0.82, 1.16) | 0.77 | 0% (0.84) | 0.94 (0.77, 1.16) | 0.56 | 0% (0.56)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.36

    Propranolol userb | 128 | 1770 | 4989 | 0.92 (0.77, 1.10) | 0.36 | 0% (0.75) | 0.97 (0.82, 1.16) | 0.77 | 0% (0.84) | 0.94 (0.77, 1.16) | 0.56 | 0% (0.56)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.78

    Propranolol | 6883 | 53,870 | 215,978 | 0.97 (0.82, 1.15) | 0.73 | 0% (0.51) | 1.03 (0.86, 1.22) | 0.78 | 3% (0.39)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.72

    Propranolol | 5426 | 55,252 | 181,959 | 0.94 (0.72, 1.21) | 0.61 | 35% (0.19) | 1.07 (0.72, 1.60) | 0.72 | 65% (0.02)

    PMID 27906047 · one of two readings recorded this

  • breast cancer-specific mortality

    no effect, p = 0.62

    Propranolol in stages 1–3 | 3389 | 44,376 | 112,450 | 1.02 (0.82, 1.26) | 0.88 | 0% (0.84) | 1.06 (0.85, 1.33) | 0.62 | 0% (0.60)

    PMID 27906047 · one of two readings recorded this

  • tamoxifen use in the year after diagnosis

    increases

    There was a higher use of hormone antagonists (tamoxifen 39% versus 30% and aromatase inhibitors 26% versus 23%, respectively) in propranolol users versus non-users

    PMID 27906047 · one of two readings recorded this

  • blood transfused

    decreases

    propranolol was associated with a lower amount of transfused blood (measured in milliliters) in adults (MD −185.64 [95% CI −331.06 to −40.43])

    PMID 28265298 · one of two readings recorded this

  • blood transfused

    no effect

    no differences in mortality (RD −0.12 [95% CI −0.32 to 0.07]) and quantity of blood transfused (MD −405 [95% CI −1343.48 to 533.48])

    PMID 28265298 · one of two readings recorded this

  • heart rate

    decreases

    Propranolol was associated with lower values of heart rate (beats per minute) when compared to usual care (MD −26.85 [95% CI −39.95 to −13.75])

    PMID 28265298 · one of two readings recorded this

  • heart rate

    decreases

    this was consistent in adults (MD −32.54 [95% CI −38.45 to −26.63]) and children (MD −19.0 [95% CI −31.12 to −6.88])

    PMID 28265298 · one of two readings recorded this

  • heart rate

    decreases

    this was consistent in adults (MD −32.54 [95% CI −38.45 to −26.63]) and children (MD −19.0 [95% CI −31.12 to −6.88])

    PMID 28265298 · one of two readings recorded this

  • hospital length of stay, pooled mean difference in days

    MD -0.37 [-4.52 to 3.78]

    Not recorded as a finding: Sentence uses a one-sided negation ('did not shorten') and continues with a qualifier about subgroups; not recordable as no_effect

    When assessing the length of hospital stay, propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78]) but this was not sustained when assessing sub-groups.

    PMID 28265298 · one of two readings recorded this

  • length of hospital stay

    no effect

    propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78])

    PMID 28265298 · one of two readings recorded this

  • length of hospital stay

    decreases

    propranolol was associated with a lower length of hospital stay in children (MD −2.0 [CI 95% −2.51 to −1.49]) and adults (MD −6.54 [95% CI −10.19 to −2.89])

    PMID 28265298 · one of two readings recorded this

  • length of hospital stay

    decreases

    the use of propranolol was associated with a lower length of hospital stay in adults (MD −6.59 [95% CI −10.18 to −3.0])

    PMID 28265298 · one of two readings recorded this

  • length of hospital stay

    decreases

    propranolol was associated with a lower length of hospital stay in children (MD −2.0 [CI 95% −2.51 to −1.49]) and adults (MD −6.54 [95% CI −10.19 to −2.89])

    PMID 28265298 · one of two readings recorded this

  • length of hospital stay

    no effect

    a fact that did not occur in children (MD 2.30 [95% CI −3.36 to 7.96])

    PMID 28265298 · one of two readings recorded this

  • mortality

    no effect

    There were no significant differences between propranolol and placebo/usual care with respect to mortality (RD −0.02 [95% CI −0.06 to 0.02])

    PMID 28265298 · one of two readings recorded this

  • mortality

    no effect

    no differences were found in the sub-group analysis when assessing this outcome in children (RD −0.02 [95% CI −0.06 to 0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07])

    PMID 28265298 · one of two readings recorded this

  • mortality

    no effect

    no differences were found in the sub-group analysis when assessing this outcome in children (RD −0.02 [95% CI −0.06 to 0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07])

    PMID 28265298 · one of two readings recorded this

  • mortality

    no effect

    no differences in mortality (RD −0.12 [95% CI −0.32 to 0.07]) and quantity of blood transfused (MD −405 [95% CI −1343.48 to 533.48])

    PMID 28265298 · one of two readings recorded this

  • overall hospital length of stay, pooled mean difference in days

    MD −0.37 [−4.52 to 3.78]

    Not recorded as a finding: Sentence 'propranolol did not shorten the overall number of days' is a one-sided negation and continues into a subgroup qualifier; node hospital-length-of-stay exists but no clean two-sided sentence.

    When assessing the length of hospital stay, propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78]) but this was not sustained when assessing sub-groups.

    PMID 28265298 · one of two readings recorded this

  • sepsis occurrence in severely burned patients, pooled risk difference

    no effect, RD -0.03 [95% CI -0.09 to 0.04]

    Not recorded as a finding: No outcome node for sepsis; infectious-complication-rate requires each source's own infectious complication case definition and sepsis is a narrower construct

    Similarly, no significant differences were found when assessing overall occurrence of sepsis (RD −0.03 [95% CI −0.09 to 0.04]) with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15]).

    PMID 28265298 · one of two readings recorded this

  • sepsis

    no effect

    no significant differences were found when assessing overall occurrence of sepsis (RD −0.03 [95% CI −0.09 to 0.04])

    PMID 28265298 · one of two readings recorded this

  • sepsis

    no effect

    with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15])

    PMID 28265298 · one of two readings recorded this

  • sepsis

    no effect

    with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15])

    PMID 28265298 · one of two readings recorded this

  • volume of blood transfused in mL, adults only

    decreases, MD -185.64 [95% CI -331.06 to -40.43]

    Not recorded as a finding: No outcome node for transfusion requirement; estimate is adults-only subgroup

    With respect to blood transfused, propranolol was associated with a lower amount of transfused blood (measured in milliliters) in adults (MD −185.64 [95% CI −331.06 to −40.43]).

    PMID 28265298 · one of two readings recorded this

  • memory valence moderator, between-group difference

    no effect, p = 0.44

    although the between-group difference was not statistically significant (Q 1 = 0.587, p = 0.44)

    PMID 35361699 · one of two readings recorded this

  • publication bias, Egger test

    p = 0.31

    The result of the Egger test was not statistically significant (p = 0.31), suggesting little risk of publication bias

    PMID 35361699 · one of two readings recorded this

  • publication bias, Egger test

    p = 0.023

    However, the result of the Egger test was statistically significant (p = 0.023), suggesting a risk of publication bias (i.e., small studies reporting large effects)

    PMID 35361699 · one of two readings recorded this

  • recall of aversive/emotional material and cue-elicited conditioned physiologic responses after memory reactivation under propranolol (healthy adults); psychiatric symptom severity and cue-induced reactivity (clinical samples); pooled Hedges g

    decreases, g = −0.51, 95 % CI −0.84 to −0.19, p = 0.002

    Not recorded as a finding: this platform holds no node for the endpoint

    As shown in Figure 2, propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002).

    PMID 35361699 · one of two readings recorded this

  • recall of aversive emotional material and cue-elicited conditioned responses after memory reactivation under propranolol versus placebo in healthy adults (pooled Hedges g); symptom severity and cue-induced physiologic reactivity in clinical samples (PTSD, addiction, phobia)

    decreases, g = -0.51, 95% CI -0.84 to -0.19 (healthy adults, recall of aversive material), p = 0.002, n = 478

    Not recorded as a finding: this platform holds no node for the endpoint

    As shown in Figure 2, propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002).

    PMID 35361699 · one of two readings recorded this

  • recall of aversive material (memory reconsolidation impairment)

    decreases, p = 0.002

    propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002)

    PMID 35361699 · one of two readings recorded this

  • symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)

    decreases, p = 0.01

    The overall effect size was moderate, and the difference was significant in favour of propranolol (g = −0.42, 95 % CI −0.74 to −0.10; p = 0.010)

    PMID 35361699 · one of two readings recorded this

  • symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)

    no effect, p = 0.29

    The overall effect size was larger for studies that involved aversive memories (e.g., trauma or phobia; g = −0.53, p = 0.016) than for those involving appetitive memories (e.g., drug-related; g = −0.27, p = 0.29)

    PMID 35361699 · one of two readings recorded this

  • symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)

    decreases, p = 0.016

    The overall effect size was larger for studies that involved aversive memories (e.g., trauma or phobia; g = −0.53, p = 0.016) than for those involving appetitive memories (e.g., drug-related; g = −0.27, p = 0.29)

    PMID 35361699 · one of two readings recorded this

  • baseline FTM Part A (tremor severity)

    no effect, p = 0.576, n = 38

    FTM score Part A | 7.15 ± 2.92 | 6.72 ± 3.14 |.576

    PMID 36806734 · one of two readings recorded this

  • baseline FTM Part B (specific motor tasks)

    no effect, p = 0.298, n = 38

    FTM score Part B | 11.75 ± 5.66 | 14.06 ± 6.60 |.298

    PMID 36806734 · one of two readings recorded this

  • baseline FTM Part C (functional disability)

    no effect, p = 0.906, n = 38

    FTM score Part C | 9.75 ± 3.61 | 9.83 ± 4.40 |.906

    PMID 36806734 · one of two readings recorded this

  • baseline FTM total score

    no effect, p = 0.558, n = 38

    FTM total score | 28.65 ± 10.18 | 30.61 ± 12.97 |.558

    PMID 36806734 · one of two readings recorded this

  • Fahn-Tolosa-Marin (FTM) clinical tremor scale total score, 1-Hz cerebellar rTMS versus oral propranolol (30 to 90 mg/day) in essential tremor

    no effect, treatment difference rTMS minus propranolol not significant on days 5, 10 and 30

    Not recorded as a finding: the comparison was against another active treatment

    Comparisons between the two groups indicated that for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639).

    PMID 36806734 · one of two readings recorded this

  • Fahn-Tolosa-Marin (FTM) tremor rating scale total score and Parts A, B, C at days 5, 10 and 30 in essential tremor, oral propranolol 30 to 90 mg/day versus 1-Hz cerebellar rTMS

    no effect

    Not recorded as a finding: the comparison was against another active treatment

    Comparisons between the two groups indicated that for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639).

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), between-group treatment difference

    no effect, p = 0.375, n = 38

    tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), between-group treatment difference

    no effect, p = 0.535, n = 38

    tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), between-group treatment difference

    no effect, p = 0.836, n = 38

    tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    no effect, p = 0.279, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    decreases, p = 0.024, n = 18

    tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    no effect, p = 0.641, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    decreases, p = 0.006, n = 20

    tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    decreases, p = 0.011, n = 20

    persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), change from baseline test

    no effect, p = 0.242, n = 20

    FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    no effect, n = 18

    FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    decreases, n = 18

    FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    no effect, n = 18

    FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    decreases, n = 20

    FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    decreases, n = 20

    FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part A (tremor severity), mean ± SD

    decreases, n = 20

    FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), between-group treatment difference

    no effect, p = 0.12, n = 38

    performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), between-group treatment difference

    no effect, p = 0.736, n = 38

    performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), between-group treatment difference

    no effect, p = 0.127, n = 38

    performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    no effect, p = 0.128, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    decreases, p = 0.013, n = 18

    tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    no effect, p = 0.645, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    decreases, p = 0.034, n = 20

    tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    decreases, p = 0.039, n = 20

    persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), change from baseline test

    no effect, p = 0.197, n = 20

    FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    no effect, n = 18

    FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    decreases, n = 18

    FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    no effect, n = 18

    FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    decreases, n = 20

    FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    decreases, n = 20

    FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73

    PMID 36806734 · one of two readings recorded this

  • FTM Part B (specific motor tasks), mean ± SD

    decreases, n = 20

    FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), between-group treatment difference

    no effect, p = 0.331, n = 38

    functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), between-group treatment difference

    no effect, p = 0.517, n = 38

    functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), between-group treatment difference

    no effect, p = 0.537, n = 38

    functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    no effect, p = 0.301, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    decreases, p = 0.026, n = 18

    tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    no effect, p = 0.823, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    no effect, p = 0.061, n = 20

    Functional disability did not differ at either time point (day 10 [p =.061], day 30 [p =.060])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    no effect, p = 0.06, n = 20

    Functional disability did not differ at either time point (day 10 [p =.061], day 30 [p =.060])

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), change from baseline test

    no effect, p = 0.549, n = 20

    FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    no effect, n = 18

    FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    decreases, n = 18

    FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    no effect, n = 18

    FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    decreases, n = 20

    FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    decreases, n = 20

    FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63

    PMID 36806734 · one of two readings recorded this

  • FTM Part C (functional disability), mean ± SD

    decreases, n = 20

    FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63

    PMID 36806734 · one of two readings recorded this

  • FTM total score, between-group treatment difference

    no effect, p = 0.147, n = 38

    for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)

    PMID 36806734 · one of two readings recorded this

  • FTM total score, between-group treatment difference

    no effect, p = 0.639, n = 38

    for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)

    PMID 36806734 · one of two readings recorded this

  • FTM total score, between-group treatment difference

    no effect, p = 0.198, n = 38

    for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    no effect, p = 0.189, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    decreases, p = 0.012, n = 18

    tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    no effect, p = 0.669, n = 18

    tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    decreases, p = 0.01, n = 20

    tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    decreases, p = 0.013, n = 20

    persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])

    PMID 36806734 · one of two readings recorded this

  • FTM total score, change from baseline test

    no effect, p = 0.155, n = 20

    FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    no effect, n = 18

    FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    decreases, n = 18

    FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    no effect, n = 18

    FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    decreases, n = 20

    FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    decreases, n = 20

    FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29

    PMID 36806734 · one of two readings recorded this

  • FTM total score, mean ± SD

    decreases, n = 20

    FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29

    PMID 36806734 · one of two readings recorded this

  • APGAR below 7 at 1 min

    no effect, n = 128

    10 (15.62%) | 9 (14.06%)

    PMID 37016326 · one of two readings recorded this

  • APGAR below 7 at 5 min

    no effect, n = 128

    1 (1.56%) | 1 (1.56%)

    PMID 37016326 · one of two readings recorded this

  • APGAR score at 1 min

    no effect, p = 0.798, n = 128

    APGAR score 1 min APGAR below 7 | Mean ± SD | 7.5 ± 0.9 | 7.45 ± 1 | 0.798 NSa

    PMID 37016326 · one of two readings recorded this

  • APGAR score at 5 min

    no effect, p = 0.312, n = 128

    APGAR score 5 min APGAR below 7 | Mean ± SD | 8.9 ± 0.6 | 8.8 ± 0.6 | 0.312 NSa

    PMID 37016326 · one of two readings recorded this

  • baseline Bishop score

    no effect, p = 0.094, n = 128

    Bishop score | Mean ± SD | 4.1 ± 1.08 | 3.8 ± 1.2 | 0.094 NSb

    PMID 37016326 · one of two readings recorded this

  • baseline body mass index

    no effect, p = 0.141, n = 128

    BMI (kg/m 2) | Mean ± SD | 26.4 ± 2.7 | 25.7 ± 2.7 | 0.141 NSa

    PMID 37016326 · one of two readings recorded this

  • baseline gestational age

    no effect, p = 0.549, n = 128

    G. Age (weeks) | Mean ± SD | 41.04 ± 1.3 | 41.2 ± 1.3 | 0.549* NSa

    PMID 37016326 · one of two readings recorded this

  • baseline maternal age

    no effect, p = 0.533, n = 128

    Age (years) | Mean ± SD | 23.3 ± 4.1 | 22.9 ± 3.2 | 0.533 NSa

    PMID 37016326 · one of two readings recorded this

  • duration of active phase

    no effect, p = 0.425, n = 84

    Duration of Active Phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 3.9 ± 2.7 | 3.5 ± 2.9 | 0.425 NS 3

    PMID 37016326 · one of two readings recorded this

  • duration of latent phase

    decreases, p = 0.017, n = 84

    Duration of Latent phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 7.9 ± 5.6 | 9.2 ± 6.03 | 0.017 S 3

    PMID 37016326 · one of two readings recorded this

  • fetal weight

    no effect, p = 0.229, n = 128

    Fetal weight (kg) | Mean ± SD | 3.45 ± 0.4 | 3.53 ± 0.4 | 0.229 NSa

    PMID 37016326 · one of two readings recorded this

  • indication of cesarean section: failed induction

    no effect, n = 44

    Failed induction (n %) | 2 | 10.5% | 1 | 4%

    PMID 37016326 · one of two readings recorded this

  • indication of cesarean section: failed progress

    no effect, p = 0.713, n = 44

    Indication of CS (19 cases in group I, 25 cases in group II) | Failed progress (n %) | 7 | 36.8% | 9 | 36% | 0.713 NS 2

    PMID 37016326 · one of two readings recorded this

  • indication of cesarean section: fetal distress

    no effect, n = 44

    Fetal distress (n) %) | 10 | 52.6% | 15 | 60%

    PMID 37016326 · one of two readings recorded this

  • indication of induction: GDM

    no effect, p = 1, n = 128

    GDM (n %) | 1 | 1.6% | 1 | 1.6% | 1.0 NS 2

    PMID 37016326 · one of two readings recorded this

  • indication of induction: HTN

    no effect, p = 0.41, n = 128

    HTN (n %) | 6 | 9.4% | 9 | 14.1% | 0.41*NS 1

    PMID 37016326 · one of two readings recorded this

  • indication of induction: post date

    no effect, p = 0.355, n = 128

    Indication of induction | Post date (n %) | 39 | 60.9% | 44 | 68.8% | 0.355 NS 1

    PMID 37016326 · one of two readings recorded this

  • indication of induction: ROM

    no effect, p = 0.08, n = 128

    ROM (n %) | 18 | 28.1% | 10 | 15.6% | 0.08 NS 1

    PMID 37016326 · one of two readings recorded this

  • induction-delivery interval

    decreases, p = 0.027, n = 84

    Induction-delivery interval (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 11.8 ± 8.1 | 12.6 ± 8.9 | 0.027 S 3

    PMID 37016326 · one of two readings recorded this

  • induction-to-delivery interval in hours after vaginal misoprostol 25 mcg induction of labor in full-term primigravidae, propranolol 20 mg versus placebo (misoprostol in both arms)

    decreases, 11.8 +/- 8.1 h vs 12.6 +/- 8.9 h, Group I vs Group II

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Table 2 shows a significantly shorter latent phase of labor in Group I when compared to Group II (7.9 ± 5.6 h. vs. 9.2 ± 6.03 h.), as well as a significantly shorter induction-delivery interval (11.8 ± 8.1 h. vs. 12.6 ± 8.9 h.).

    PMID 37016326 · one of two readings recorded this

  • induction-to-delivery interval in hours among primigravidae delivering vaginally (primary), and duration of the latent phase of labor in hours; oral propranolol 20 mg plus vaginal misoprostol versus placebo plus vaginal misoprostol

    decreases, 11.8 vs 12.6 h induction-delivery interval; 7.9 vs 9.2 h latent phase, propranolol group versus placebo group

    Not recorded as a finding: this platform holds no node for the endpoint

    Table 2 shows a significantly shorter latent phase of labor in Group I when compared to Group II (7.9 ± 5.6 h. vs. 9.2 ± 6.03 h.), as well as a significantly shorter induction-delivery interval (11.8 ± 8.1 h. vs. 12.6 ± 8.9 h.).

    PMID 37016326 · one of two readings recorded this

  • misoprostol doses needed: 1 dose

    no effect, p = 0.79, n = 84

    Misoprostol dose (No. of doses) (45 cases in group I, 39 cases in group II) | 1 dose (n %) | 14 | 31.1% | 14 | 35.9% | 0.79 NS 2

    PMID 37016326 · one of two readings recorded this

  • misoprostol doses needed: 2 doses

    no effect, n = 84

    2 dose (n %) | 28 | 62.2% | 22 | 56.4%

    PMID 37016326 · one of two readings recorded this

  • misoprostol doses needed: 3 doses

    no effect, n = 84

    3 dose (n %) | 2 | 4.4% | 2 | 5.1%

    PMID 37016326 · one of two readings recorded this

The whole record — 601 rows